Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 8/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17571634 | 0.82 | ATM (0.52) | ATMNPSR1ARPARP1PRMT5 | |
| SCHEMBL29214135 | 0.78 | ATM (0.51) | ATMNPSR1ARPARP1PRMT5 | |
| SCHEMBL29643994 | 0.78 | KDM4E (0.52) | KDM4EALDH1A1GAA | |
| SCHEMBL561564 | 0.78 | KDM4E (0.52) | KDM4EALDH1A1GAA | |
| SCHEMBL23087789 | 0.77 | PRMT5 (0.44) | ATMNPSR1ARPARP1PRMT5 | |
| SCHEMBL29915098 | 0.77 | PRMT5 (0.44) | ATMNPSR1ARPARP1PRMT5 | |
| Hydrochloric Acid SCHEMBL31208116 | 0.76 | KDM4E (0.50) | KDM4EALDH1A1GAA | |
| SCHEMBL1032659 | 0.72 | PRMT5 (0.60) | ATMNPSR1ARPARP1PRMT5 | |
| SCHEMBL7502157 | 0.71 | CYP11B1 (0.51) | LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL7502145 | 0.71 | CYP11B1 (0.51) | LMNAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-20060217388-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO | 2006-09-28 | — | — | US | disclosed |
| EP-1165085-B1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6911440-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2005-06-28 | — | — | US | disclosed |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2004-07-22 | — | — | US | disclosed |
| US-6686347-B2 | RHEUMATIC DISEASES; ANALGESICS; ENZYME INHIBITORS | NOVARTIS AG (CH) | 2004-02-03 | — | — | US | disclosed |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2003-01-16 | — | — | US | disclosed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | disclosed |
| WO-1993013092-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | SARGES REINHARD (US) | 1993-07-08 | — | — | WO | disclosed |
| US-5011840-A | Imidazolidinedione derivatives in diabetes treatment | PFIZER INC. (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0269355-B1 | IMIDAZOLIDINEDIONE DERIVATIVES | PFIZER INC. (US) | 1991-04-10 | — | — | EP | disclosed |
| EP-0269355-A1 | Imidazolidinedione derivatives | PFIZER INC. (US) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, KDR, FFAR2 | ATM 4232/4885NPSR1 857/4885AR 860/4885 |
| US-20060217388-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, NR2E3, FLT1 | ATM 1663/4885NPSR1 1999/4885AR 1529/4885 |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, FLT1, TIE1 | ATM 2823/4885NPSR1 785/4885AR 2012/4885 |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, FLT4, KDR | ATM 3761/4885NPSR1 685/4885AR 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.